BridgeBio Pharma BBIO Cost of license, services, and royalty revenue — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's cost of license, services, and royalty revenue — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's cost of license, services, and royalty revenue — revenue?
- BridgeBio Pharma (BBIO) reported cost of license, services, and royalty revenue — revenue of $10.3M in Q1 2026.
- What does cost of license, services, and royalty revenue — revenue mean?
- Total revenue earned from licensing intellectual property, providing services, and receiving royalties.
- How do you interpret cost of license, services, and royalty revenue — revenue?
- An increase indicates successful monetization of the company's intellectual property portfolio and strong demand for its research and development partnerships.
- How does cost of license, services, and royalty revenue — revenue compare across companies?
- Comparable to 'Licensing and Royalty Revenue' or 'Collaboration Revenue' reported by other biopharma companies that utilize partnership-heavy business models.